LB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timeline

Reuters2026/07/22 12:04

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

LB Pharmaceuticals posted a press release accelerating expected topline timing for Phase 3 NOVA-2 data for LB-102 in schizophrenia to H1 2027.
Pre-NDA meeting with the FDA now targeted for H2 2027.
NOVA-2 plans to enroll about 460 patients across 25 U.S. sites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220800PRIMZONEFULLFEED9766044) on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

LB Pharmaceuticals releases update on NOVA-2 Phase 3 schizophrenia trial timeline

You may also like

Crypto prices